Key Highlights

  • Compass Pathways (NASDAQ:CMPS) traded near USD 12.00 early in the session of Wednesday, October 21, 2026, up 0.84%, at a market value near USD 1.66 billion and about 72% higher for the year.
  • Phase 3 results in treatment-resistant depression, reported on Tuesday, July 7, 2026, moved the psilocybin therapy COMP360 towards a new drug application, and 52-week data followed on Wednesday, September 9, 2026.
  • The company held about USD 433 million in cash at June 30 and reported a second-quarter net loss of USD 253.8 million, with no product revenue.
  • The 109.03% change in basic EPS rests on a negative base in a company without sales, so it reflects the size of losses and non-cash items, not commercial progress.

Phase 3 Data and a Path to Filing

Compass Pathways (NASDAQ:CMPS), a biotechnology company developing COMP360, a synthetic psilocybin therapy, traded near USD 12.00 early in the session of Wednesday, October 21, 2026. Market data put the year-to-date gain near 72.5% at the close of Tuesday, October 20, 2026, when the shares ended near USD 11.90. The company reported Phase 3 results in treatment-resistant depression, meaning depression that has not responded to at least two standard treatments, on Tuesday, July 7, 2026. On Wednesday, September 9, 2026, it released 52-week open-label data from the COMP005 trial showing durability to one year, and the shares rose 8.05% that day. COMP360 holds Breakthrough Therapy designation from the FDA. The company had not issued a release accounting for the most recent move.

Why the EPS Change Says Little About Value

The 109.03% change in basic earnings per share at Compass Pathways (NASDAQ:CMPS) is a percentage move in a negative figure, in a company with no product revenue. The second-quarter net loss of USD 253.8 million was close to the full-year 2025 loss of USD 269.8 million. In 2025 the operating loss was USD 179.0 million, so about USD 90.8 million of the annual loss came from items below operating income, simple arithmetic on reported figures. Such items in biotechnology often include fair-value changes on warrants, which rise when the share price climbs. The valuation therefore rests on the probability and timing of approval. Cash of about USD 433 million at June 30 funds the path to a decision, while an effective shelf registration allows further equity sales.

Risks and What to Watch

The first risk for Compass Pathways (NASDAQ:CMPS) is regulatory, because approval requires an FDA decision and a separate rescheduling of psilocybin by the Drug Enforcement Administration. Company materials point to a potential launch in the first half of 2027, contingent on both steps. The second is dilution, since an automatic shelf registration filed on Wednesday, August 5, 2026 allows the company to raise equity quickly. The third is positioning, with short interest near 13.3% of the float, which can amplify moves either way. Treatment delivery also requires clinic time and monitoring, which may slow uptake. Investors should watch confirmation of the new drug application, third-quarter results on Tuesday, November 3, 2026 and any FDA communication on review timing.

Where Things Stand

The answer is that Compass Pathways (NASDAQ:CMPS) is priced for a reasonable chance of approval after positive Phase 3 data, with a market value near USD 1.66 billion against cash of about USD 433 million. The 109.03% EPS change rests on losses and non-cash items, not on sales. The next catalysts are the new drug application, results on November 3 and FDA review signals. Clinical and regulatory outcomes are uncertain, and this is not investment advice.